CoChat

Infigratinib: First Approval

Open access
Kang, Connie · 2021 · Drugs

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

), a fibroblast growth factor receptor (FGFR)-specific tyrosine kinase inhibitor, is being co-developed by QED Therapeutics and Helsinn for the treatment of cholangiocarcinoma, urothelial carcinoma and other FGFR-driven conditions. Infigratinib was recently approved in the USA for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement as detected by a test approved by the US Food and Drug Administration. This article summarizes the milestones in the development of infigratinib leading to this first approval for advanced cholangiocarcinoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40265-021-01567-1

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Figures

Key milestones in the development of infigratinib. CCA cholangiocarcinoma, NDA New Drug Application
Key milestones in the development of infigratinib. CCA cholangiocarcinoma, NDA New Drug ApplicationCC BY-NC · PubMed Central
Chemical structure of infigratinib
Chemical structure of infigratinibCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 1

  1. Reyes M, Zamora C, Andrews S, et al. A phase I, open-label, single-dose study to evaluate the excretion and mass balance, pharmacokinetics, and metabolism of [14C]-infigratinib (BGJ398) in healthy adult volunteers [abstract no. PIII-045]. Clin Pharmacol Ther. 2021;109(Suppl 1):S57.

Cited by

See all 109

Metadata

Authors
Kang, C.
Affiliations
Springer Nature (New Zealand) (NZ)
Corresponding author
Kang, Connie
Venue
Drugs
Published
2021-07
Volume
81
Issue
11
Pages
1355-1360
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
OpenAlex
W3186228217
Cited by
101
References
7
Citations by year
2026: 15 · 2025: 19 · 2024: 29 · 2023: 20 · 2022: 17 · 2021: 1
FWCI
15.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Drugs (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by-nc)
  • Figshare
Topics
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Keywords
infigratinib, FGFR tyrosine kinase inhibitors, cholangiocarcinoma, FGFR2 fusion, drug approval, drug development milestones, urothelial carcinoma
MeSH terms
Antineoplastic Agents, Humans, Neoplasm Metastasis, Phenylurea Compounds, Pyrimidines, United States, United States Food and Drug Administration, Receptors, Fibroblast Growth Factor, Cholangiocarcinoma, Receptor, Fibroblast Growth Factor, Type 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Infigratinib: First Approval. https://app.cochat.ai/papers/10.1007/s40265-021-01567-1
The paper
Kang, C. (2021). Infigratinib: First Approval. Drugs. https://doi.org/10.1007/s40265-021-01567-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.